Castle Biosciences Inc reports results for the quarter ended in June - Earnings Summary

Castle Biosciences

08/08/2022 23:02

* Castle Biosciences Inc  CSTL.OQ  reported a quarterly
adjusted
loss of 84 cents​​ per share for the quarter ended in June. The
mean expectation of seven analysts for the quarter was for a
loss of 76 cents per share.
    * Revenue rose 53.1% to $34.84 million from a year ago;
analysts
expected $28.38 million. 
    * Castle Biosciences Inc's reported EPS for the quarter was
a loss
of 84 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Castle Biosciences Inc shares had risen by 39.2% this
quarter and lost 28.7% so far this year.
    * The company reported a quarterly loss of $26.27 million.
    * Wall Street's median 12-month price target for Castle
Biosciences Inc is $45.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 8
at 10:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.76          -0.84          Missed
 Mar. 31 2022      -0.71          -0.97          Missed
 Dec. 31 2021      -0.47          -0.25          Beat
 Sep. 30 2021      -0.40          -0.47          Missed